Carregant...
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
Recently, the focus of enhancing tumor radiosensitivity has shifted from chemotherapeutics to targeted therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are a novel class of selective cell cycle therapeutics that target the cyclin D-CDK4/6 complex and induce G1 phase arrest. These agent...
Guardat en:
| Publicat a: | J Exp Clin Cancer Res |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7490904/ https://ncbi.nlm.nih.gov/pubmed/32933570 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01693-w |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|